MiCo BioMed Balance Sheet Health
Financial Health criteria checks 2/6
MiCo BioMed has a total shareholder equity of ₩17.5B and total debt of ₩12.0B, which brings its debt-to-equity ratio to 68.6%. Its total assets and total liabilities are ₩38.3B and ₩20.8B respectively.
Key information
68.6%
Debt to equity ratio
₩11.97b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩4.32b |
| Equity | ₩17.45b |
| Total liabilities | ₩20.82b |
| Total assets | ₩38.27b |
Financial Position Analysis
Short Term Liabilities: A214610's short term assets (₩22.1B) exceed its short term liabilities (₩16.0B).
Long Term Liabilities: A214610's short term assets (₩22.1B) exceed its long term liabilities (₩4.8B).
Debt to Equity History and Analysis
Debt Level: A214610's net debt to equity ratio (43.8%) is considered high.
Reducing Debt: Insufficient data to determine if A214610's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A214610 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: A214610 has less than a year of cash runway if free cash flow continues to grow at historical rates of 3.8% each year.